Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
P/E ratio for Pharming Group N.V. (PHAR)
P/E ratio as of 2023: -71.20
According to Pharming Group N.V.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -71.20. At the end of 2022 the company had a P/E ratio of 57.04.
P/E ratio history for Pharming Group N.V. from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -71.20 |
| 2022 | 57.04 |
| 2021 | 34.46 |
| 2020 | 22.49 |
| 2019 | 24.74 |
| 2018 | 33.29 |
| 2017 | -7.26 |
| 2016 | -35.72 |
| 2015 | -57.73 |
| 2014 | -77.94 |
| 2013 | -12.53 |
| 2012 | -2.92 |
| 2011 | -2.75 |
| 2010 | -0.45 |
| 2009 | -0.30 |
| 2008 | -0.30 |
| 2007 | -0.20 |
| 2006 | -0.45 |
| 2005 | -0.53 |